

Shenzhen Ivankaca Technology Co., Ltd
% Long Yang
Coo
Shenzhen Hlongmed Biotech Co., Ltd.
1201, Haosheng Business Center, 4096 Dongbin Road, Nanshan,
Shenzhen, P.R.C
Shenzhen, 518054 Cn

Re: K201397

Trade/Device Name: Ultrasonic Mesh Nebulizer Regulation Number: 21 CFR 868.5630 Regulation Name: Nebulizer Regulatory Class: Class II Product Code: CAF Dated: June 14, 2021 Received: June 14, 2021

Dear Long Yang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <u>https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems</u>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</u>) and CDRH Learn (<u>https://www.fda.gov/training-and-continuing-education/cdrh-learn</u>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</u>) for more information or contact DICE by email (<u>DICE@fda.hhs.gov</u>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Brandon Blakely, PhD
Acting Assistant Director
DHT1C: Division of ENT, Sleep Disordered
Breathing, Respiratory and
Anesthesia Devices
OHT1: Office of Ophthalmic, Anesthesia,
Respiratory, ENT and Dental Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number *(if known)* K201397

Device Name Ultrasonic Mesh Nebulizer

Indications for Use (Describe)

The Ultrasonic Mesh Nebulizer designed to aerosolized liquid medications for inhalation by patient, the device may be used with pediatric (>4 years of age), defined by the prescribed medication, and adult patients in the home, hospital and sub-acute care settings.

It is not intended for use with Pentamidine.

Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov*

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirement of SMDA 1990 and Title 21, CFR Section 807.92.

The assigned 510(K) number is:_____ Date of Summary: 2021.6.2

1. Submitter information

.

Manufacturer Name: Shenzhen Ivankaca Technology Co.,Ltd

Address: 3/F, Building B, No.45 lixin road, NanWan, Longgang, Shenzhen, Guangdong, China

Contact Person and Title: Sam WONG/General manager

Tel: 0086- 755-28510161

Fax: 0086- 755-28510161

Email: <u>798401644@qq.com</u>

Date Prepared: June 2, 2021

2. Contact person

2.1 Primary Contact Person

Long Yang (COO) Shenzhen Hlongmed Biotech Co.,Ltd 1201, Haosheng Business Center, 4096 Dongbin Road, Nanshan, Shenzhen, P.R.C Tel: 0086-755-86664986 Fax: 0086-755-86664933 E-mail: yanglong@hlongmed.com

2.2 Secondary Contact Person

Sam WONG/General manager Shenzhen Ivankaca Technology Co.,Ltd Tel: 0086- 755-28510161

3. Proposed device

Type of 510(k) submission	Traditional
Trade Name name	Ultrasonic Mesh Nebulizer
Common Name	Nebulizer
Model(s)	MY-123, MY-125, MY-126
Classification Name	Nebulizer (Direct Patient Interface)
Classification	П
Review Panel	Anesthesiology
Product Code	CAF
Regulation Class	П
Regulation Number	21 CFR 868.5630

4. Predicate device

510(k) Number:

K171549

Predicate Device Name:

Intelligent Mesh Nebulizer (model: NEB002)

Manufacturer:

Qingdao Future Medical Technology Co., Ltd This predicate has not been subject to a design-related recall. No reference devices were used in this submission.

5. Description of Proposed Device

The proposed devices are vibrating mesh nebulizers that use low frequency vibration to create aerosol and deliver aerosolized medication to the lower respiratory tract by using a vibrating mesh to create aerosol and provide fine particles to the patient's lungs. The mesh plate has holes to create low velocity aerosol.

The proposed devices are portable size, curvaceous body design that is convenient to hold, Which are battery powered, 3.7V d.c. internally lithium battery. The medication


container capacity is 8ml maximum.

.

For devices, they are pushed by certain circuit frequency vibration to make piezoelectric ceramic vibrate harmony that caused high speed vibration of metal mesh. And the medicine liquid will be quickly popped through micro mesh hole of metal mesh plate to be countless micro atomizing particles. This will be further transferred by inhalation treatment using masks or mouthpieces to patients' respiratory system.


There are 3 models included, MY-123/MY-125/ MY-126, the three models have same intended use, mechanism of action, principle and specification. The difference between three models is appearance.

The proposed devices have the components shown as following illustration:





.



MY-126

Figure 1 Device Components illustration

The contents provided in the Table are description about the components.

Main Unit	Provide electricity
Atomizing	filled with medicine liquid
Cup	
Mesh Plate	Create low velocity aerosol
	ON/OFF the nebulizer
	Press the ON/OFF button for 3s to turn on the power and press turn off
ON/OFF	again;
button	The nebulizer will shut down automatically after 5min operation. Press
	on /off for 3S to start the machine when it is still in use
	Blue light on when the nebulizer works regularly;
Indicator	Automatic turn off after blue light flashes when the battery is running
	out electricity;
light	Blue lights flicker on when charging regularly;
	Green light on while finishing charging;
USB	Connect the nebulizer with the USB cable to 5Vd.c 1.0A min.
interface	power supply to recharge .

Mask	Transport the aerosol to patient's respiratory system.
Mouthpiece	Transport the aerosol to patient's respiratory system.

Table 1 Main Components of Device introduction

The associated accessories include Mouthpiece, Adult Mask, Pediatric Mask, USB charging cable.

6. Intended Use/ Indications for Use

.

The Ultrasonic Mesh Nebulizer designed to aerosolized liquid medications for inhalation by patient, the device may be used with pediatric (>4 years of age), defined by the prescribed medication, and adult patients in the home, hospital and sub-acute care settings.

It is not intended for use with Pentamidine.

7. Technological Characteristics and Substantial Equivalence

Item	Subject Device	Predicate device	Remark							
General Comparison										
K	/	K171549	/							
Sponsor	Shenzhen Ivankaca Technology	Qingdao Future Medical Technology	/							
	Co.,Ltd	Co., Ltd								
Trade/Device	Ultrasonic Mesh Nebulizer	Intelligent Mesh Nebulizer	/							
Name										
Model(s)	MY-123	NEB002	/							
	MY-125									
	MY-126									
Regulation	21 CFR 868.5630	21 CFR 868.5630	same							
Number										
Regulation	Nebulizer	Nebulizer	same							
Name										
Classification	Nebulizer (Direct Patient Interface)	Nebulizer (Direct Patient Interface)	same							
Name										

Regulatory	Class II	Class II	same
Class Product Code	CAF	CAF	same
Review Panel	Anesthesiology	Anesthesiology	same
Intended	The Ultrasonic Mesh Nebulizer	The Intelligent Mesh Nebulizer	same
Use/	designed to aerosolized liquid	designed to aerosolized liquid	Same
Indications	medications for inhalation by	medications for inhalation by	
for Use	patient, the device may be used with	patient, the device may be used with	
loi Use	pediatric (>4 years of age), defined	pediatric (>4 years of age) and adult	
	by the prescribed medication, and	patients in the home, hospital and	
	adult patients in the home, hospital	sub-acute care settings.	
	and sub-acute care settings.	It is not intended for use with	
	It is not intended for use with	Pentamidine.	
	Pentamidine.	rentamidine.	
Prescription/	Prescription	Prescription	same
OTC			
Performance	Comparison		
Lithium	3.7Vd.c.	3.7Vd.c.	Same
battery			
Nebulizing	Vibrating Mesh	Vibrating Mesh	same
Method			
Vibration	Approx. 110KHz	Approx. 110KHz	same
Frequency			
Nebulization	0.2ml/min minimum	0.2ml/min minimum	same
Rate/Aerosol			
Flow rate			
Medicine	8ml maximum,0.5ml minimum	8ml maximum,0.5ml minimum	same
Capacity			
Nebulizer	Yes	Yes	same
Components			
Cleanable			
Use	Single Patient	Single Patient	same
Patient	Mouthpiece or mask	Mouthpiece or mask	same
Connector			
Dimensions	Approx.	50mm(L)×74mm(W)×111mm(H)	differen
(mm)	42(L)x55(W)x109(H)mm(MY-123)		
	49(L)x56(W)x120(H)mm(MY-125)		
	45(L)x47(W)x120(H)mm(MY-126)		
Weight (kg)	MY-123:113±5g	Approx.106g	differen
	MY-125:116±5g		

.

r			
	MY-126: 110±5g		
Operating	5°C to 40°C, 15% to 90% RH	5°C to 40°C, 15% to 90% RH	same
Conditions			
Storage	-25°C to 70°C, ≤90% RH	-25 °C to 70 °C, ≤90% RH	same
Conditions			
Safety Compa	arison		
Patient	PVC	PVC	same
Contact			
Materials			
Cytotoxicity	Comply with 10993-1	Comply with 10993-1	same
Sensitization			
Irritation			
Electrical	Comply with 60601-1	Comply with 60601-1	same
safety			
EMC	Comply with 60601-1-2	Comply with 60601-1-2	same

Comparative particle test comparison can be refer to the following table:

.

Item	Subject Device		Subject Device			Subject Device			Intelligent Mesh Nebulizer (model: NEB002) -K171549				
		Mouthpiece			Small mask			Big mask	_		Big mask		
	Salbutam	Budesoni	Ipratropi	Salbutam	Budesoni	Ipratropi	Salbutam	Budesoni	Ipratropi	Salbutam	Budesoni	Ipratropi	
	ol	de	um	ol	de	um	ol	de	um	ol	de	um	
	(Ventolin	(Pulmico	bromide	(Ventolin	(Pulmico	bromide	(Ventolin	(Pulmico	bromide	(Ventolin	(Pulmico	bromide	
)	rt))	rt))	rt))	rt)		
MMAD(µm)	3.68±0.68	3.28±0.08	3.84 ±	3.75±0.63	3.25±0.11	3.85 ±	3.72±0.65	3.31±0.10	3.88 ±	3.70±0.66	3.29±0.12	3.87 ±	
			0.66			0.66			0.68			0.72	
GSD	1.84±0.03	2.44±0.02	1.83 ±	1.86±0.05	2.46 ±	1.84 ±	1.82 ±	2.48 ±	1.84 ±	1.85±0.04	2.50 ±	1.81 ±	
			0.035		0.025	0.035	0.035	0.031	0.032		0.033	0.03	
Respirable	63.5% ±	61.7% ±	62.4%	63.8% ±	60.8 % ±	63.4%	64.5% ±	58.8 % ±	64.5%	62.8% ±	57.6% ±	63.8%	
fraction	10.5	10.5	± 10.6	11.8	11.6	± 11.3	10.2	10.2	± 11.9	11.3	9.8	± 11.6	
1 - 5 μm													
Coarse particle	36.1% ±	29.1% ±	36.2%	33.4% ±	27.4% ±	35.4%	38% ±	30.5 % ±	33.8%	37.2% ±	31.6% ±	34.4%	
fraction >5 μm	11.3	11.3	± 12.1	13.0	13.0	± 12.2	10.8	12.3	±12.4	12.3	11.9	± 12.3	
Fine particle	65.4% ±	70.9% ±	63.8%	64.8% ±	69.6% ±	64.6%	66.6% ±	69.5 % ±	66.2%	67.7% ±	68.4% ±	65.6%	
fraction (FPF<5	11.4	11.3	± 12.1	12.6	13.0	±12.2	13.0	10.3	±12.4	10.2	10.8	± 12.3	
μm)													
Ultra-fine particle	2.7% ±	9.2% ±	1.79%	2.2% ±	8.8% ±	1.77%	2.8% ±	7.2% ±	1.8% ±	3.2% ±	7.5% ±	1.78%	
fraction <1 µm	0.9	0.8	± 0.6	0.8	1.2	± 0.5	1.2	0.9	0.6	0.6	1.1	± 0.6	

Item	Item Subject Device		e	Subject Device			Subject Device			Intelligent Mesh Nebulizer (model: NEB002) -K171549			
		Mouthpiece			Small mask			Big mask			Big mask		
	Salbutam	Budesoni	Ipratropi	Salbutam	Budesoni	Ipratropi	Salbutam	Budesoni	Ipratropi	Salbutam	Budesoni	Ipratropi	
	ol	de	um	ol	de	um	ol	de	um	ol	de	um	
	(Ventolin	(Pulmico	bromide	(Ventolin	(Pulmico	bromide	(Ventolin	(Pulmico	bromide	(Ventolin	(Pulmico	bromide	
)	rt))	rt))	rt))	rt)		
residual (%)	29.6% ±	26.9% ±	23.8% ±	28.6% ±	24.3% ±	23.6% ±	30.8% ±	24.17% ±	24.5% ±	31.5% ±	24.42% ±	26.3% ±	
	5.2	5.8	3.53	4.4	5.4	3.52	5.8	4.82	3.58	4.66	4.96	3.61	
rate of recovery	93.3% ±	96.4% ±	91.7% ±	91.7% ±	95.87% ±	92.6% ±	92.6% ±	95.07% ±	92.6% ±	91.2% ±	94.86% ±	93.3% ±	
(%)	3.66	4.83	4.52	4.52	3.85	2.83	2.83	2.52	2.83	4.28	2.65	3.66	
Aerosol output	1.94 ±	1.86 ±	1.94 ±	1.93 ±	1.88 ±	1.94 ±	1.95 ±	1.87 ±	1.93 ±	1.96 ±	1.85 ±	1.92 ±	
and aerosol output rate	0.02	0.011	0.02	0.05	0.01	0.02	0.01	0.01	0.03	0.01	0.012	0.02	
Aerosol output													
(ml) ^a													
Aerosol output	0.29 ±	0.27 ±	0.35 ±	0.30 ±	0.28 ±	0.34 ±	0.32 ±	0.28 ±	0.35 ±	0.32 ±	0.26 ±	0.33 ±	
rate (ml/min) ^b	0.02	0.02	0.02	0.03	0.02	0.02	0.03	0.02	0.02	0.03	0.02	0.02	
Dead volume	0.06 ±	0.14 ±	0.06 ±	0.07 ±	0.12 ±	0.06 ±	0.05 ±	0.13 ±	0.07 ±	0.04 ±	0.15 ±	0.08 ±	
(ml)	0.02	0.011	0.02	0.05	0.01	0.02	0.01	0.01	0.03	0.01	0.012	0.02	
Respirable dose	0.70ml ±	0.758ml	0.58ml	0.71ml ±	0.76ml ±	0.59ml	0.73ml ±	0.78ml ±	0.60ml	0.72ml ±	0.77ml ±	0.58ml	
1 - 5 μm													

.

Item	Subject Device		e	Subject Device			Subject Device			Intelligent Mesh Nebulizer (model: NEB002) -K171549			
		Mouthpiece		Small mask		Big mask			Big mask				
	Salbutam	Budesoni	Ipratropi	Salbutam	Budesoni	Ipratropi	Salbutam	Budesoni	Ipratropi	Salbutam	Budesoni	Ipratropi	
	ol	de	um	ol	de	um	ol	de	um	ol	de	um	
	(Ventolin	(Pulmico	bromide	(Ventolin	(Pulmico	bromide	(Ventolin	(Pulmico	bromide	(Ventolin	(Pulmico	bromide	
)	rt))	rt))	rt))	rt)		
	0.11	±0.15	±0.11	0.12	0.20	±0.11	0.12	0.20	±0.12	0.12	0.18	±0.12	
Delivered dose	1.12ml ±	1.23ml ±	0.93ml	1.12ml ±	1.26ml ±	0.93ml	1.14ml ±	1.27ml ±	0.94ml	1.13ml ±	1.24ml ±	0.92ml	
	0.06	0.12	±0.02	0.08	0.1	±0.02	0.08	0.1	±0.02	0.08	0.12	±0.02	

a: Continue the treatment until the medicine cup is empty or the mist stops.

b: The treatment time for aerosol output rate is 1 min.

·

Analysis for difference:

The proposed devices have the same Intended Use, Classification, Nebulizing Method, Vibration Frequency, Aerosol Flow rate, Medicine Capacity, Operation and use with the predicate device.

The proposed devices have the similar specifications with the predicate device, such as dimensions ,Weight, based on the nonclinical tests performed, those minor differences for specifications do not effects the safety and effective of the device.

The proposed devices are substantially equivalent to the predicate device. Based on the nonclinical tests performed, the subject devices are as safe, as effective, and performs as well as the legally marketed predicate device.

8. Non-clinical Test conclusion

The following performance data were provided in support of the substantial equivalence determination.

a.Biocompatibility testing

The nebulizer's mouthpiece, Big mask, Small mask, Atomizing cup, Seal ring, Atomizing cup cover, nozzle,Mesh plate are patient-contacting device components.

No	patient-contacting	associated materials of	If color	patient-contact
	device components	construction for each	additive	classifications per ISO
		component	contained	10993-1
1	mouthpiece	PP1120	no	• Surface Contact
2	Big mask	PP1120	no	• Mucosal membrane
		TPE(TE-KJ3025TM)	no	• Duration of Use(> 30
3	Small mask	PP1120	no	days)
		TPE(TE-KJ3025TM)	no	
4	Atomizing cup	PC2456	no	• External
5	Seal ring	Silicone GA1053	no	Communicating
6	Atomizing cup cover	PC2456	no	(Indirect gas
7	nozzle	PC2456	no	pathway)

8	Mesh plate	Stainless304	no	•	Tissue / Bone /
					Dentin
					communicating
				•	Duration of Use(> 30
					days)

A biocompatibility evaluation for the proposed device was conducted in accordance with FDA 's 2020 Guidance entitled, "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". The evaluation included the following tests:

- In Vitro Cytotoxicity Test -ISO10993-5
- Skin Sensitization Test(polar and non polar) -ISO10993-10
- Intracutaneous Reactivity Test-ISO10993-10
- Acute Systemic Toxicity Test (polar and non polar) -ISO10993-11
- Ames Test (polar and DMSO Extract)--ISO10993-3
- In Vitro Mammalian Chromosomal Aberration test --ISO10993-3
- Mammalian Erythrocyte Micronucleus Test(polar and non polar) -- ISO10993-3
- Subcutaneous Implantation Test--ISO10993-6
- Test for emissions of VOCs and aldehydes-ISO 18562-3
- Test for emissions of particulate matter ozone CO2 and CO- ISO 18562-2
- Biocompatibility evaluation- ISO 18562-1

Under the parameters of the tests it is concluded that they are biocompatible, and that there are no new issues of safety regarding their use as intended.

b. Electrical Safety and Electromagnetic Compatibility (EMC)

Electrical safety and EMC testing were conducted on the device. Testing established that, with respect to electrical safety, the device meets the applicable requirements of:

AAMI/ANSI ES60601-1:2005/(R)2012 and A1:2012, C1:2009/(R)2012 and A2:2010/(R)2012 (Consolidated Text) Medical electrical equipment - Part 1: General requirements for basic safety and essential performance (IEC 60601-1:2005, MOD)

- IEC 60601-1-2:2014 Medical electrical equipment Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests
- IEC 60601-1-11:2015 Medical electrical equipment Part 1-11: General requirements for basic safety and essential performance - Collateral Standard: Requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment

c. Software Verification and Validation Testing

The software for this device is of a "moderate" level of concern, Verification and validation testing was conducted in accordance with, and documentation was provided as recommended by FDA 's Guidance, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, May 1, 2005".

d. Simulated shelf life testing, battery cycle life testing

e. Cleaning and Disinfection Validation

f. human factors validation testing

g. **Particle size distribution testing** per Section VII of the FDA Guidance: Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators, and three kind of drugs used for each testing, Salbutamol (Ventolin), Budesonide (Pulmicort), Ipratropium bromide.

9. Clinical Test Conclusion

No clinical study is included in this submission.

10. Substantial Equivalence Conclusion

Based on the comparison and analysis above, the proposed device is determined to be Substantially Equivalent (SE) to the predicate device.